Longevity in the body : The antibody component of MariTide provides it with a longer half-life in the body, enhancing its effectiveness and reducing the frequency of administration Bispecific nature : The combination of anti-GIPR monoclonal antibody and GLP-1 receptor agonist in one molecule helps in achieving more significant weight loss than using either agent alone Clinical development MariTide is currently undergoing Phase 2 clinical trials, with Amgen focusing on demonstrating its efficacy with a once-monthly injection regimen
Liver Int (2016) 36 Suppl 1:11623
They are typically reserved for experienced users, those with higher body mass, or those pursuing very aggressive goals (e.g., competitive bodybuilding or severe injury recovery)
Age, genetics, baseline facial volume, skin elasticity, smoking history, sun damage, nutrition, and the degree of muscle loss all influence how visible the change becomes